Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 14 May 2021, including: issues surrounding the proposed IP waiver for coronavirus vaccines; a trial delay for Novavax, Inc.’s COVID-19 vaccine; an ICER review of multiple myeloma drugs; and Galapagos NV’s efforts to refocus its R&D pipeline.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?" - Scrip, 12 May, 2021.)
(Also see "India’s COVID-19 Nightmare And How Pharma Is Holding Up" - Scrip, 6 May, 2021.) Starts at 2:43
(Also see "After Another Covid Vaccine Delay, Novavax’s Opportunity Is Shrinking" - Scrip, 11 May, 2021.) Starts at 4:25
(Also see "BCMA Drug Prices For Multiple Myeloma Don't Match Their Benefit, ICER Concludes" - Scrip, 12 May, 2021.) Starts at 6:19
(Also see "Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence" - Scrip, 11 May, 2021.) Starts at 8:21